EGFR and non-small cell lung carcinoma: In recently reported large-scale randomized studies including JO25567 [11], NEJ026[12], and RELAY [13–15], the addition of anti-angiogenic drugs to EGFR TKIs substantially improved PFS in TKI-naive patients with EGFR-mutant NSCLC.